Sacral nerve modulation for irritable bowel syndrome: A randomized, double‐blinded, placebo‐controlled crossover study

2019 ◽  
Vol 31 (6) ◽  
pp. e13570 ◽  
Author(s):  
Janne Fassov ◽  
Lilli Lundby ◽  
Søren Laurberg ◽  
Klaus Krogh
2014 ◽  
Vol 260 (1) ◽  
pp. 31-36 ◽  
Author(s):  
Janne L. Fassov ◽  
Lilli Lundby ◽  
Søren Laurberg ◽  
Steen Buntzen ◽  
Klaus Krogh

2020 ◽  
Vol Volume 13 ◽  
pp. 235-244
Author(s):  
Janne Fassov ◽  
Donghua Liao ◽  
Christina Brock ◽  
Lilli Lundby ◽  
Søren Laurberg ◽  
...  

BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e018362 ◽  
Author(s):  
Joong Il Kim ◽  
Pumsoo Kim ◽  
Jin-Hyun Lee ◽  
Yoo-Jin Kim ◽  
Na-rae Yang ◽  
...  

IntroductionIrritable bowel syndrome (IBS), known as a functional and organic gastrointestinal disorder, is a collection of symptoms that occur together and generally include pain or discomfort in the abdomen and changes in bowel movement patterns. Due to the limitations of conventional treatments, alternative IBS treatments are used by many patients worldwide. Samryungbaekchulsan (SRS), a herbal formula, has long been used for alleviating diarrhoea-predominant IBS (D-IBS) in traditional Korean medicine. Otilonium bromide (OB) is an antimuscarinic compound used to relieve spasmodic pain in the gut, especially in IBS. Although herbal formulae and Western drugs are commonly coadministered for various diseases in Korea, few clinical studies have been conducted regarding the synergic effects of these treatments for any disease, including D-IBS.Methods and analysisThis trial is a randomised, double-blinded, placebo-controlled, double-dummy, four-arm, parallel study. After a 2-week preparation period, 80 patients with D-IBS will be randomly assigned to one of four treatment groups consisting of SRS (water extract granules, 5 g/pack, three times a day) with OB (tablet form, one capsule three times a day) or their placebos, with treatment lasting for 8 weeks. Post-treatment follow-up will be conducted 4 weeks after the end of treatment. The primary outcome is the finding obtained using the Subject’s Global Assessment of Relief method. The secondary outcomes are the severity of symptoms related to D-IBS, determined using a 10-point scale, and the change in symptoms.Ethics and disseminationThis trial has full ethical approval of the Ethics Committee of Catholic Kwandong University International St. Mary’s Hospital (IS15MISV0033) and the Korean Ministry of Food and Drug Safety (30769). The results of the study will be disseminated through a peer-reviewed journal and/or conference presentations.Trial protocol versionIS15MISV0033 version 4.0 (25 July 2016).Trial registration numberKCT0001621(approval date: 10 August 2015).


2014 ◽  
Vol 60 (1) ◽  
pp. 186-194 ◽  
Author(s):  
Reuben K. Wong ◽  
Cao Yang ◽  
Guang-Hui Song ◽  
Jennie Wong ◽  
Khek-Yu Ho

Gut ◽  
1987 ◽  
Vol 28 (2) ◽  
pp. 221-225 ◽  
Author(s):  
M R Lucey ◽  
M L Clark ◽  
J Lowndes ◽  
A M Dawson

Sign in / Sign up

Export Citation Format

Share Document